Inhaled Insulin

Technosphere insulin, a rapid-acting human insulin administrated through an inhaler, was associated with reductions in HbA1c at 30 weeks for adults with type 1 diabetes, according to findings from the INHALE-3 extension trial.

ORLANDO — An inhaled insulin was noninferior to usual care for change in HbA1c and continuous glucose monitoring metrics among adults with type 1 diabetes, according to data from the INHALE-3 trial.

A form of inhaled insulin has been available for adults with type 1 and type 2 diabetes for nearly a decade, but providers say many people are not aware that it may be a treatment option for them.

CMS will now allow Medicare beneficiaries with diabetes to use any insulin along with continuous glucose monitor therapy and eliminate a four times per day testing requirement, part of a policy change to the local coverage determination.

Among adults with type 2 diabetes, inhaled insulin was associated with HbA1c reductions similar to those with insulin aspart, fewer hypoglycemic episodes and lower body weight, according to a study published in Endocrine Practice.